TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04516135

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-Dimensional Conformal Radiation Therapy
Description: Undergo 3D CRT

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 3-Dimensional Conformal Radiation Therapy
Description: Undergo 3D CRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Volume Modulated Arc Therapy
Description: Undergo VMAT
Study: NCT04912986

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Lung Rehabilitation Training
Description: It is implemented in accordance with the Early Lung Rehabilitation Training Program for Adult Double Lung Transplant Patients. Establish multidisciplinary collaboration teams, including competent doctors, nurses, rehabilitation physicians, and psychologists.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Routine treatment
Description: Provide rehabilitation training as usual, without standard program
Study: NCT04975451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib plus DCb
Study: NCT05157035

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness/Acceptance-Based Smartphone App (MABSA)
Description: This is a mindfulness- and acceptance-based smartphone app. The mindfulness and acceptance exercises embedded in the app are based on the principles of Acceptance and Commitment Therapy. Participants in the intervention group will be using the app for 6 weeks. They are expected to access the meditations and mindfulness exercises within the app on a daily basis.
Study: NCT06458257

Intervention type: PROCEDURE
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Allogeneic Hematopoietic Stem Cell Transplantation

Intervention type: DRUG
Intervention: Chemotherapy
Description: Chemotherapy
Study: NCT04516135

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Volume Modulated Arc Therapy
Description: Undergo VMAT
Study: NCT04926623

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FreeStyle Libre 24 weeks
Description: FreeStyle Libre flash sensor-based glucose monitoring system (FSGM; Abbott Diabetes Care, Witney, Oxon, UK)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FreeStyle Libre 24 weeks
Description: FreeStyle Libre flash sensor-based glucose monitoring system (FSGM; Abbott Diabetes Care, Witney, Oxon, UK)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SMBG (22 weeks) and blind CGM (2 weeks)
Description: Self-Monitoring of Blood Glucose and Continuous Glucose Monitoring
Study: NCT04209062

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medical device validation
Description: The medical devices will both record electrical signals for comparison

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medical device validation
Description: The medical devices will both record electrical signals for comparison
Study: NCT05191563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1904-1
Description: Take it once per period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1904-1
Description: Take it once per period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLD2006
Description: Take it once per period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLD2006
Description: Take it once per period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLD2001-2
Description: Take it once per period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLD2001-2
Description: Take it once per period.
Study: NCT00646919

Intervention type: PROCEDURE
Intervention: Nose swab
Study: NCT05859256

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental
Description: The intervention consists of the application of a treatment protocol based on an initial active warm-up consisting of 3 active exercises, walking for 1 minute performing slow and controlled movement of the ankle, raising the heels, 15 repetitions, dorsiflexion of the ankle in the standing position. gentleman, 15 reps. Subsequently, the floss band will be placed, performing again the 3 active warm-up exercises with the band on. After this, the passive manual techniques will be carried out for the remaining time, removing the flossing at the end of the latter, and actively mobilizing again.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: The same procedures will be carried out, but placing the flossing without tension and performing the Kaltenborn manual techniques without sliding and without joint mobilization.
Study: NCT06077448

Intervention type: DEVICE
Intervention: MRI
Description: imaging modality

Intervention type: DEVICE
Intervention: MRI
Description: imaging modality
Study: NCT05885854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XTR003
Description: Enrolled subjects were required to fast for ≥ 6 hours before drug administration at rest;~1. Initial intravenous injection of 18F-FDG to each subject with a dose range of 2.0-3.0 mCi (74-111 MBq). Each patient will be imaged with PET for 10 minutes at 50-70 minutes after the injection.~2. In few minutes, a single intravenous bolus injection of XTR003 will follow and administer to each patient with a dose range of 6.0-8.0 mCi (222-296 MBq). Each patient will be immediately imaged with PET for 15 minutes.
Study: NCT06557525

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurofeedback
Description: Subjects will receive neurofeedback training by visual stimulation using a software program on a PC or tablet (monitor) with reference to EEG data acquired with a portable electroencephalograph (EEG) to provide feedback on the state of the DLPFC in the brain. The DLPFC status of the subject's brain is then fed back to the subject to continue stimulating the subject's reward system. Before and after these neurofeedback training sessions, fMRI imaging will be performed to confirm changes in brain activity.
Study: NCT05318339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: A loading dose of trastuzumab 8mg/kg IV over 90 minutes will be administrated on day 1 of week 1.~For all subsequent doses, trastuzumab 6mg/kg IV over 30 minutes will be administrated every three weeks.~Pyrotinib 400mg PO daily will be administrated at the same time.
Study: NCT04258514

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Virtual Reality during vasectomy
Description: Virtual Reality

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard Vasectomy
Description: No Virtual Reality
Study: NCT05036369

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibrant capsule
Description: Vibrant capsule - Administered twice a week (Monday and Thursday).

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: Placebo Capsule administered twice a week (Monday and Thursday)
Study: NCT05977712

Intervention type: OTHER
Intervention: Questionnaire
Description: The questionnaire includes information on socio-demographics (age, sex, education, occupation, marital status), behavioural (smoking, alcohol consumption, social functioning), and health-related factors (morbidities, treatment, sleep disturbance, eye diseases, frailty, falls).

Intervention type: OTHER
Intervention: Questionnaire
Description: The questionnaire includes information on socio-demographics (age, sex, education, occupation, marital status), behavioural (smoking, alcohol consumption, social functioning), and health-related factors (morbidities, treatment, sleep disturbance, eye diseases, frailty, falls).

Intervention type: OTHER
Intervention: Clinical examination
Description: This includes earing test, cognitive tests (mini-mental status examination, MemScreen), body mass index, waist circumference, blood pressure and blood tests (biomarkers of Alzheimer's disease, neurodegeneration, and other dementias).

Intervention type: OTHER
Intervention: Clinical examination
Description: This includes earing test, cognitive tests (mini-mental status examination, MemScreen), body mass index, waist circumference, blood pressure and blood tests (biomarkers of Alzheimer's disease, neurodegeneration, and other dementias).

Intervention type: OTHER
Intervention: Accelerometer port
Description: Participants will be wearing an accelerometer for 9 days.

Intervention type: OTHER
Intervention: Accelerometer port
Description: Participants will be wearing an accelerometer for 9 days.
Study: NCT06105255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-1553
Description: D-1553 is a novel, targeted KRASG12C inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-1553
Description: D-1553 is a novel, targeted KRASG12C inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-1553
Description: D-1553 is a novel, targeted KRASG12C inhibitor.
Study: NCT06211374

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Communication Bridge
Description: Evidence-based speech language therapy treatment will be compared and contrasted in the two arms of the study.
Study: NCT05703126

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: History taking
Description: Careful history taking, including using questionnaires, to identify risk factors for the development of cardiovascular diseases using the SCORE scale.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: History taking
Description: Careful history taking, including using questionnaires, to identify risk factors for the development of cardiovascular diseases using the SCORE scale.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Anthropometry
Description: Anthropometry: measurement of body weight and height. Calculation of body surface area using the Du Bois formula.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Anthropometry
Description: Anthropometry: measurement of body weight and height. Calculation of body surface area using the Du Bois formula.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Complete blood count
Description: Before and after each course of chemotherapy: Complete blood count with counting the number of erythrocytes, leukocytes, leukocyte formula, platelets, erythrocyte sedimentation rate.
Study: NCT05977712

Intervention type: OTHER
Intervention: Eye examination
Description: Eye fundus photo, OCT and OCT-A exams
Study: NCT05101551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Talazoparib will be administered in escalating doses based on current dose level.~* Dose Level 1: 400 µg/m2/dose once daily~* Dose Level 2: 600 µg/m2/dose BID on Day 1, then daily on Days 2 to 5~* Dose Level 3: 600 µg/m2/dose BID on Day 1, then daily on Days 2 to 5~* Dose Level 4: 600 µg/m2/dose BID on Day 1, then daily on Days 2 to 5~* Dose Level 5: 600 ug/m2/dose BID on Day 1, then daily on Days 2 to 5 and 15 to19

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: Administered IV route on Days 1 to 5~* Dose Level -2: 1 mg/m2/dose once daily by IV days 1 to 5~* Dose Level -1: 2 mg/m2/dose once daily by IV days 1 to 5~* Dose Level 1: 2 mg/m2/dose once daily by IV days 1 to 5~* Dose Level 2: 2 mg/m2/dose once daily by IV days 1 to 5~* Dose Level 3: 3 mg/m2/dose once daily by IV days 1 to 5~* Dose Level 4: 4 mg/m2/dose once daily by IV days 1 to 5~* Dose Level 5: 4 mg/m2/dose once daily by IV days 1 to 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Single dose (IV) of gemcitabine on Day 1 of each 28 day cycle for 1 cycle.~* Dose Level -2: 600 mg/m2/dose once daily by IV days 1~* Dose Level -1: 600 mg/m2/dose once daily by IV days 1~* Dose Level 1: 1200 mg/m2/dose once daily by IV days 1~* Dose Level 2: 1200 mg/m2/dose once daily by IV days 1~* Dose Level 3: 1200 mg/m2/dose once daily by IV days 1~* Dose Level 4: 1200 mg/m2/dose once daily by IV days 1~* Dose Level 5: 1200 mg/m2/dose once daily by IV days 1
Study: NCT05912400

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood draw
Description: • An additional 10 mL of blood will then be drawn for mitochondrial testing purposes.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood draw
Description: • An additional 10 mL of blood will then be drawn for mitochondrial testing purposes.

Intervention type: OTHER
Intervention: FACIT-F and Pain Scales
Description: • Questionnaires regarding pain and fatigue will be provided for the subject to review and answer.
Study: NCT06060509

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Phytosterol-rich Wheat and Corn Germ Blended Oil
Description: Blending of corn germ oil and wheat germ oil supplied by Yihai Kerry to obtain germ blended oil with high phytosterol content.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Peanut oil
Description: Participants in the control group consumed peanut oil daily for cooking.
Study: NCT04794634

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography (OCT)
Description: to make a complete ophthalmological and neurological examination, an OCT to AD and to compare their results with LD and controls subjects

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography (OCT)
Description: to make a complete ophthalmological and neurological examination, an OCT to AD and to compare their results with LD and controls subjects

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Optical coherence tomography (OCT)
Description: to make a complete ophthalmological and neurological examination, an OCT to AD and to compare their results with LD and controls subjects

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Optical coherence tomograpohy angiography (OCTA)
Description: to make a complete ophthalmological and neurological examination, an OCT and OCTA, to AD and to compare their results with LD and controls subjects

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Optical coherence tomograpohy angiography (OCTA)
Description: to make a complete ophthalmological and neurological examination, an OCT and OCTA, to AD and to compare their results with LD and controls subjects

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Optical coherence tomograpohy angiography (OCTA)
Description: to make a complete ophthalmological and neurological examination, an OCT and OCTA, to AD and to compare their results with LD and controls subjects
Study: NCT05516277

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Sleep Education Intervention
Description: Manual-based education program focusing on behavioral sleep provided in individual 60-minute sessions for 5 weekly sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: General Sleep Education Intervention
Description: Manual-based education program focusing on general sleep provided in individual 60-minute sessions for 5 weekly sessions.
Study: NCT06110572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given by IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given by IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: Undergo Total Body Irradiation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiation Therapy
Description: Undergo Hypofractionated Radiation Therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo Magnetic Resonance Imaging
Study: NCT06427759

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: arm aesthetic surgery
Description: liposuction of arms brachioplasty of arms
Study: NCT05698056

Intervention type: OTHER
Intervention: No intervention.
Description: No intervention.
Study: NCT05133908

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Hygiene and Self-Monitoring Control
Description: An app with self-monitoring function and videos and written materials about sleep hygiene will be provided.
Study: NCT05626725

Intervention type: DEVICE
Intervention: Automated insulin delivery system
Description: This is an outpatient prospective observational study to evaluate the effect of DIY-AID use on maintaining glucose levels in physically active adult people living with T1D.
Study: NCT04039490

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SCENERGY
Description: Use of the SCENERGY guidance device in conjunction with ultrasound to guide needles for pediatric vessel cannulations
Study: NCT05553587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amara drops
Description: The investigational drug is approved with a reduced dossier without indication according to Art. 25 para. 1 KPAV (SR 812.212.24). This study follows the indication text licensed by Swissmedic: ... Weleda Amara-Drops can be used for digestive complaints such as heartburn, flatulence and bloating after meals, to stimulate the bile flow and for loss of appetite and nausea. The effect of Weleda Amara drops is based on a balanced mixture of medicinal plants with tonic (invigorating) and aromatic bitter substances, which are suitable for stimulating digestion. Further, no side effects have been reported in past studies so far. All these reasons lead us to the conclusion that this study is only associated with minimal risks and should be classified in risk category A.
Study: NCT06375187

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Engineering Tumor Infiltrating Lymphocytes
Description: A tumor sample is resected from each participant and cultured ex vivo to generate the engineered tumor infiltrating lymphocytes. After lymphodepletion, patients are infused GC203 TIL followed low-dose PD-1 antibody.
Study: NCT04141878

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Exercise
Description: Participants will follow a structured program that includes exercise 3 times per week for about 30 minutes each time. The type of aerobic exercise may vary, but will primarily focus on walking tutorials.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet Skills
Description: Participants will attend weekly classes focused on incorporating heart healthy foods into their existing diets. Calories will be restricted, and portion control will be taught with the goal of losing body weight. Hands-on skills will be taught for preparing healthy home-cooked meals by professional chefs.
Study: NCT06232772

Intervention type: DIAGNOSTIC_TEST
Intervention: α- Synuclein Ultrafine Fluorescence Detection Method
Description: This technology belongs to the detection of a-syn aggregates in extracranial tissues, which can replace brain biopsy operations that are difficult to carry out clinically, thus breaking through the limitations of clinical experience in diagnosing a-synuclein lineage diseases and greatly improving the diagnostic and differential diagnostic level of this group of diseases.

Intervention type: DIAGNOSTIC_TEST
Intervention: α- Synuclein Ultrafine Fluorescence Detection Method
Description: This technology belongs to the detection of a-syn aggregates in extracranial tissues, which can replace brain biopsy operations that are difficult to carry out clinically, thus breaking through the limitations of clinical experience in diagnosing a-synuclein lineage diseases and greatly improving the diagnostic and differential diagnostic level of this group of diseases.

Intervention type: DIAGNOSTIC_TEST
Intervention: α- Synuclein Ultrafine Fluorescence Detection Method
Description: This technology belongs to the detection of a-syn aggregates in extracranial tissues, which can replace brain biopsy operations that are difficult to carry out clinically, thus breaking through the limitations of clinical experience in diagnosing a-synuclein lineage diseases and greatly improving the diagnostic and differential diagnostic level of this group of diseases.

Intervention type: DIAGNOSTIC_TEST
Intervention: α- Synuclein Ultrafine Fluorescence Detection Method
Description: This technology belongs to the detection of a-syn aggregates in extracranial tissues, which can replace brain biopsy operations that are difficult to carry out clinically, thus breaking through the limitations of clinical experience in diagnosing a-synuclein lineage diseases and greatly improving the diagnostic and differential diagnostic level of this group of diseases.

Intervention type: DIAGNOSTIC_TEST
Intervention: α- Synuclein Ultrafine Fluorescence Detection Method
Description: This technology belongs to the detection of a-syn aggregates in extracranial tissues, which can replace brain biopsy operations that are difficult to carry out clinically, thus breaking through the limitations of clinical experience in diagnosing a-synuclein lineage diseases and greatly improving the diagnostic and differential diagnostic level of this group of diseases.
Study: NCT06270095

Intervention type: DIAGNOSTIC_TEST
Intervention: Neurocognitive, neuromuscular and neurosensitive tests.
Description: At T0, the subject realizes a neurocognive test and an self-assessment of health symptoms autonomously on its professional digital tablet. They also realizes two self questionnaires on their state of fatigue (Samn-Perelli Fatigue Scale) and anxiety (Hospital Anxiety and Depression scale).~At T0 + 3 months, the subject follows a standardized medical examination carried out by a physician, assessing neuromuscular score using the Medical Research Council questionnaire and assessing neurosensitivity score using the Incat Sensory Sum Score. If necessary, the DN4 questionnaire for neuropathic pain is used. The same neurocognitive tests than T0, and Samn-Perelli Fatigue Scale and Hospital Anxiety and Depression scale are also repeated.

Intervention type: DIAGNOSTIC_TEST
Intervention: Neurocognitive, neuromuscular and neurosensitive tests.
Description: At T0, the subject realizes a neurocognive test and an self-assessment of health symptoms autonomously on its professional digital tablet. They also realizes two self questionnaires on their state of fatigue (Samn-Perelli Fatigue Scale) and anxiety (Hospital Anxiety and Depression scale).~At T0 + 3 months, the subject follows a standardized medical examination carried out by a physician, assessing neuromuscular score using the Medical Research Council questionnaire and assessing neurosensitivity score using the Incat Sensory Sum Score. If necessary, the DN4 questionnaire for neuropathic pain is used. The same neurocognitive tests than T0, and Samn-Perelli Fatigue Scale and Hospital Anxiety and Depression scale are also repeated.